Pfizer cuts some more, closing R&D site in Singapore

As Pfizer ($PFE) continues to cut costs, it has just taken the ax to a clinical research facility in a market where others are beefing up: Singapore. Pfizer says it will close up shop at leased space at Raffles Hospital in Singapore in midyear and let go of about 30 staffers there. The drug giant is trying to trim another $1.3 billion from its R&D budget this year. It has been shaving its R&D operations for several years, FierceBiotech reports, and has cut other clinical research facilities, like its operation in Sandwich, U.K., and move of research away from Groton, CT. Other companies are building in Singapore, like Amgen ($AMGN). The biotech said last month that it would spend $200 million to build a manufacturing plant there. Story | More

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.